The rising geriatric population is a major factor expected to drive the expansion of the hip tendinitis market over the next few years. The population of older adults is increasing at a higher rate than any other age group as analyzed by the World Health Organization (WHO). Its statistical observations further suggest that the number of people over 60 years is anticipated to exceed 2 billion mark by the end of 2050. It is projected to act as a growth catalyst for the hip tendinitis market over the next couple of years.
Hip tendonitis is a condition where the tendons present in the hip and pelvis joints that support the bodyweight get damaged. Multiple factors have been recognized that triggers the disease and is likely to affect a larger section of the population in the years to come. Market Research Future (MRFR)’s assessment has asserted that the global hip tendinitis market is expected to expand at a CAGR of 4.55% during the forecast period 2017 to 2023. It is also expected to scale a decent valuation by the end of the forecast period.
The concerns raised by the sedentary lifestyle is motivating the masses to shift towards sports and other physical activities for maintaining health and avoiding cardiovascular diseases. However, a drastic increase in injuries during sports has been observed in the recent years. This is one of the major factors responsible for the expansion of the hip tendinitis market currently. It is anticipated to has a similar influence on the growth pattern of the market in the forthcoming years.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4764
Some of the other factors that are likely to boost the growth pace of the hip tendinitis market in the forthcoming future are lack of exercise, research & development, and increasing patient population of rheumatoid arthritis & diabetes. This, is projected to encourage the key players to focus on the development of more effective drugs and diagnosis, thus, augmenting the hip tendinitis market in the foreseeable future.
Key players for global hip tendinitis market
- Almatica Pharma, Inc
- Bayer AG
- Boehringer Ingelheim Pharmaceuticals, Inc
- Merck & Co., Inc
- GlaxoSmithKline plc
- Teva Pharmaceuticals
- Lupin Pharmaceuticals, Inc.
- Geri-Care Pharmaceuticals.
- Perrigo Company
The global hip tendinitis market is segmented on the basis of types, treatment, and end users.
On the basis of types, the market is segmented into internal snapping hip, external snapping hip, and intra-articular snapping hip.
On the basis of treatment, the market is segmented into diagnosis and therapy. The diagnosis is further segmented into physical exam, imaging tests, and others. Imaging test is further segmented into ultrasound, magnetic resonance imaging (MRI) scans, and others. The therapy is segmented into pharmacological, non-pharmacological, shock wave or surgery, medical devices, and others. The pharmacological therapy is further segmented into OTC drugs, corticosteroids injections, platelet-rich plasma (PRP), and others. The medical devices are further segmented into mechanical band, support tape, pre-cut strips, continuous rolls, and others.
On the basis of end users, the market is segmented into hospitals & clinics, medical research centers, academic institutes, and others.
The global hip tendinitis market is dominated by America owing to the presence of huge geriatric population and continuous increasing number of diabetic patients. As per the report published by the population reference bureau, in 2015, the number of Americans ageing over 65 were 46 million, which is expected to reach over 98 million by 2060. Furthermore, increasing number of patients suffering form rheumatoid arthritis, changing lifestyle, and huge healthcare spending have boosted the growth of the market in America. According to the American Diabetes Association, over 30.3 million Americans population were suffering from diabetes in 2015. Additionally, increasing awareness among the people regarding different types of diseases and increasing government support is likely to contribute to the growth of the market during the review period 2017-2023.
Europe accounts for the second largest hip tendinitis market, which is followed by Asia Pacific. According to the Eurostat, in 2016, 19.2% of total European population were over age 65 years. Increasing geriatric population and adoption of sports by the people may drive the market growth. Moreover, availability of funds for research, and government support for research & development are expected to fuel the market growth.
Asia Pacific is the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, and the presence of huge opportunity in the market. On the other hand, the Middle East & Africa holds the least share in the global hip tendinitis market due to presence of poor economy, especially, in African region. The Middle East holds the major share of the Middle East & African market owing to the well-developed healthcare sector and huge healthcare expenditure.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hip-tendinitis-market-4764